wwwchestpubsorg
report
surviv
among
patient
cwp
similar
indic
lung
transplant
six
eight
miner
remain
aliv
mean
followup
day
transplant
enfi
eld
et
al
univers
virginia
also
recent
review
outcom
patient
multipl
center
underw
lung
transplant
sever
cwp
sinc
use
databas
unit
network
organ
share
univers
virginia
analysi
account
ing
age
lung
alloc
score
type
transplant
surviv
transplant
appear
signifi
cantli
lower
patient
cwp
compar
non
miner
patient
copd
interstiti
lung
diseas
howev
independ
exact
prognosi
cwp
transplant
realiti
advanc
cwp
medic
treatment
may
amelior
symptom
revers
lung
damag
halt
progress
fi
brotic
process
agre
lung
transplant
must
consid
option
particularli
younger
miner
develop
disord
dr
diazguzman
colleagu
encourag
increas
awar
advanc
cwp
earli
referr
transplant
center
recognit
massiv
fi
brosi
coal
miner
often
progress
even
remov
dust
exposur
concur
medic
commun
need
effect
enhanc
awar
continu
human
toll
dust
diseas
assur
optim
medic
care
fair
compens
affect
miner
progress
massiv
fi
brosi
entir
prevent
sinc
virtual
caus
excess
dust
inhal
occur
tobacco
use
caus
effect
dust
control
elimin
type
lung
diseas
modern
mine
industri
failur
us
industri
tackl
ongo
problem
highlight
intern
addit
draw
attent
role
lung
transplant
improv
surviv
function
statu
patient
hope
report
fi
nding
motiv
time
implement
necessari
effect
measur
reduc
dust
exposur
provid
health
work
environ
countri
coal
miner
wade
aw
petsonk
el
young
b
mogri
sever
occup
pneumoconiosi
among
west
virginian
coal
miner
one
hundr
thirtyeight
case
progress
massiv
fi
bro
si
editor
bafadhel
colleagu
report
recent
issu
chest
june
serum
procalcitonin
level
high
patient
admit
hospit
pneumonia
admit
exacerb
asthma
copd
examin
use
serum
procalcitonin
patient
moder
sever
exacerb
asthma
due
infect
recruit
patient
men
confi
rmed
diagnosi
asthma
consid
infect
exacerb
increas
symptom
measur
sevenpoint
likert
scale
increas
sputum
volum
purul
sever
enough
requir
hospit
none
patient
radiolog
evid
pneumonia
spirometri
perform
nasopharyng
swab
sputum
obtain
virolog
bacteri
cultur
quantit
cell
count
measur
repeat
week
symptom
complet
resolv
procalcitonin
measur
serum
time
exacerb
week
procalcitonin
measur
duplic
l
serum
use
timeresolv
amplifi
ed
cryptat
emi
sion
technolog
assay
kryptor
trace
pct
brahm
berlin
germani
lower
limit
detect
ngml
assay
function
sensit
ngml
sputum
e
c
serum
procalcitonin
ngml
valu
given
mean
sd
unless
otherwis
note
e
eosinophil
n
neutrophil
tcc
total
cell
count
symptom
cough
chest
tight
wheez
short
breath
measur
sevenpoint
likert
score
best
worst
b
median
interquartil
rang
c
median
minimummaximum
editor
thank
dr
dsilva
colleagu
interest
recent
articl
chest
asthma
exacerb
consid
associ
virus
current
guidelin
advoc
use
antibiot
exacerb
asthma
interestingli
dr
dsilva
colleagu
identifi
ed
virus
case
bacteria
copd
bacteri
infect
implic
major
caus
exacerb
current
evid
support
use
antibiot
manag
mild
moder
exacerb
whether
patient
asthma
bacterialassoci
exacerb
benefi
antibiot
therapi
uncertain
howev
detail
analysi
microbiolog
asthma
exacerb
use
standard
molecular
techniqu
warrant
other
found
procalcitonin
strongli
associ
exacerb
copd
asthma
elev
patient
pneumonia
therefor
good
biomark
system
infl
ammatori
respons
pneumonia
may
potenti
clinic
util
direct
antibiot
therapi
importantli
valu
procalcitonin
might
greater
wide
avail
creactiv
protein
control
trial
antibiot
direct
biomark
creactiv
protein
sputum
cell
count
exacerb
asthma
copd
requir
biomarkerguid
therapi
commonplac
medic
specialti
cardiolog
approach
need
urgent
investig
embrac
respiratori
medicin
make
chang
manag
exacerb
airway
diseas
leicest
england
